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Purpose: To assess the effect of diuretic administration on
the image quality of excretory magnetic resonance urogra-
phy (MRU) obtained following intravenous hydration, and
to determine whether intravenous hydration alone is suffi-
cient to produce diagnostic quality studies of nondilated
upper tracts.
Materials and Methods: A total of 22 patients with nondi-
lated upper tracts were evaluated with contrast-enhanced
MRU. All patients received 250 mL of saline intravenously
immediately prior to the examination. A total of 11 patients
received 10–20 mg furosemide in addition to saline. Imag-
ing was performed with a three-dimensional (3D) and two-
dimensional (2D) breathhold spoiled gradient-echo se-
quences. Excretory MRU images were acquired five
minutes after the administration of 0.1 mmol/kg gadolin-
ium and were independently reviewed by two radiologists,
who were blinded to the MRU technique. Readers evaluated
the calyces, renal pelvis, and ureters qualitatively for de-
gree of opacification, distention, and artifacts on a four-
point scale. Statistical analysis was performed using a per-
mutation test.
Results: There was no significant disagreement between
the two readers (P  0.14). Furosemide resulted in signifi-
cant improvement in calyceal and renal pelvis distention
(P  0.005), and significant artifact reduction in all upper
tract segments (P  0.001) compared to the effect of saline
alone.
Conclusion: Intravenous furosemide significantly im-
proves the image quality of excretory MRU studies obtained
following intravenous hydration. Intravenous saline alone
is insufficient to produce diagnostic quality studies of the
non-dilated upper tracts.
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MR UROGRAPHY (MRU) permits evaluation of the uri-
nary tract without the exposure to ionizing radiation
and iodinated contrast medium. Two imaging strategies
have been developed for MRU: nonenhanced MRU,
which is performed using heavily T2-weighted (T2-W)
sequences; and contrast-enhanced MRU (CE-MRU),
which is performed with fast T1-weighted (T1-W) pulse
sequences following intravenous gadolinium adminis-
tration (1–14).
Heavily T2-W sequences, such as the single-shot fast
spin-echo (SSFSE) sequence, utilizing thin-slice and
thick-slice imaging techniques, provide static images of
fluid in the urinary tract and are particularly useful for
evaluating dilated systems (1–8). T2-W MRU has sev-
eral limitations. These include the relatively low reso-
lution of the sequences used, superimposition of hyper-
intense extraurinary fluid collections on thick slice MR
urography, and the inability to visualize nondilated
ureters. Moreover, T2-W MRU provides no functional
information (9–13).
Excretory CE-MRU is the technique most commonly
used to evaluate the nondilated collecting system (10–
14). After excretion of intravenous gadolinium chelates
by the kidneys, fluid within the upper tracts becomes
visible on T1-W sequences, allowing for their assess-
ment. The rapid pulse sequences used for imaging sig-
nificantly reduce motion artifacts, enable evaluation of
the renal parenchyma, and provide at least gross renal
functional information (10–15).
Since low-dose (5–20 mg) intravenous furosemide ad-
ministration has been recommended for excretory CE-
MRU to improve visualization of the nondilated upper
tracts (10–12,14), it is conceivable that intravenous
fluid administration alone may have the same effect,
obviating the need to administer an intravenous drug
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with its potential, albeit low, side effects. The objective
of our study is to compare the image quality of excretory
MRU studies obtained following intravenous hydration
without and with intravenous furosemide, and to deter-
mine whether intravenous hydration alone is sufficient




A total of 44 consecutive CE-MRU studies were per-
formed between August 2001 and May 2002. Initially,
MRU studies performed at our institution were done
with intravenous fluid only and without furosemide
(N  21) in an attempt to avoid intravenous drug ad-
ministration. However, due to artifacts seen on some
studies, we began using intravenous furosemide rou-
tinely for all patients undergoing CE-MRU (N  23),
except those with markedly dilated upper tracts. The
upper tracts represent the intrarenal collecting system
(calyces and renal pelvis) and ureters.
All 44 MRU studies were retrospectively reviewed to
identify patients with nondilated upper tracts. The up-
per tracts were characterized as nondilated if the caly-
ces were not visualized on the coronal T2-W SSFSE
localizer sequence, or they were seen as a thin line of
hyperintense signal intensity. Renal pelvis dilatation
without calyceal dilatation was considered normal and
related to an extrarenal pelvis. A total of 22 patients,
including five women and 17 men, were identified and
constituted our study population. These patients were
referred for conventional MR imaging and CE-MRU to
evaluate for known or suspected genitourinary tract
pathology including known renal cell carcinoma (RCC)
(N  6) and transitional cell carcinoma (TCC) (N  5),
suspected renal mass (N  5), hematuria (N  4), flank
pain (N  1), and congenital anomaly (N  1). The mean
patient age was 50 years (range  37–94 years). Six
patients had undergone unilateral nephrectomy (N  4)
and nephroureterectomy (N  2) for RCC and TCC,
respectively. Serum creatinine levels ranged between
0.6 and 2.2 mg/100 mL. Institutional review board
approval was sought and obtained for this retrospective
study and the need for a consent form was waived.
All 22 patients with nondilated upper tracts were
classified in two groups: Group A (N  11) included
those who received 250 mL saline only prior to starting
the MR study (mean age  53.9 years, range  37–81
years, mean creatinine level  1.62 mg/100 mL,
range  0.6–2.2 mg/100 mL); Group B (N  11) in-
cluded those patients who, in addition to 250 mL sa-
line, received intravenous furosemide immediately
prior to intravenous gadolinium administration (mean
age  67 years, range  37–93 years, mean creatinine
level  1.35 mg/100 mL, range  0.9–2.1 mg/100 mL).
There was no statistically significant difference between
the creatinine levels in the two groups (P  0.23; un-
paired t-test). Saline was given as a bolus injection
immediately prior to laying the patient on the scanning
table. The dose of furosemide varied according to the
serum creatinine level and was increased with increas-
ing serum creatinine level as follows: 10 mg for patients
with serum creatinine levels below 1.5 mg/100 mL; 15
mg for patients with levels between 1.5–2 mg/100 mL;
and 20 mg for patients with levels over 2 mg/100 mL.
Furosemide was given as a slow intravenous injection
over one minute immediately prior to injecting the in-
travenous gadolinium to achieve the maximum diuretic
effect, which helps expand the intrarenal collecting sys-
tem, and minimize possible washout of excreted gado-
linium due to increased diuresis (10).
MR Imaging
All 22 conventional MRI/MRU studies were performed
on a 1.5-T scanner (General Electric Medical Systems,
Milwaukee, WI, USA) using a four-element torso
phased-array coil. The imaging sequences used were as
follows:
1. Coronal and axial T2-W SSFSE localizers (TR 
1000 msec, TE 90 msec, number of excitations
[NEX]  0.5, slice thickness/intersectional gap 
8 mm/2 mm, matrix size  256  128–160 [fre-
quency  phase]).
2. Axial T1-W breathhold dual-echo spoiled gradient
echo (SPGR) through kidneys (TR  155 msec,
TE  2.3 msec/4.6 msec [out-of-phase/in-phase],
flip angle  70°, NEX  1, slice thickness/gap  6
mm/0 mm, matrix size  256  160 [frequency 
phase]). This sequence is used to detect and char-
acterize renal and adrenal lesions.
3. Axial T2-W fat-suppressed fast spin-echo (FSE)
through the liver and kidneys (TR  3650–4600
msec, TE  96–98 msec, NEX  2–4, slice thick-
ness/gap  6 mm/0 mm, matrix size  256 
224–256 [frequency  phase], echo train length 
8–12, respiratory triggering). This sequence is
used predominantly to detect and characterize he-
patic, renal, and adrenal lesions, and to identify
enlarged lymph nodes.
4. Coronal T1-W breathhold three-dimensional
SPGR (3D SPGR) (TR  6.8–7.5 msec, TE  1.4–
2.2 msec, flip angle  12°, NEX  0.5, section
thickness  2.6–3.6 mm, matrix size  256–
320  160–256 [frequency  phase], frequency
selective fat saturation, phase-encoding direc-
tion  right-left, scan time  24–29 seconds)
through kidneys and bladder before and following
gadolinium administration in the cortical (30 sec-
onds) and nephrographic (one minute) phases of
enhancement (16). These images are used to eval-
uate the renal arteries and veins, renal paren-
chyma, and assess for the presence of early en-
hancing TCC in the upper tracts and bladder.
Coronal imaging was repeated in the excretory
phase at five minutes following gadolinium admin-
istration using the same sequence with the same
parameters except for the flip angle, which was
increased to 35° to suppress the background sig-
nal from abdominal organs and emphasize the ga-
dolinium-enhanced urine in the upper tracts. The
excretory phase images are used to evaluate the
morphology of the contrast column in the upper
tracts, and detect filling defects (usually TCC) that
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distort this column. Scanning of each of these
phases (pre-gadolinium, cortical, nephrographic,
and excretory) was performed during 24–29-sec-
ond breathholding.
5. Axial excretory phase T1-W SPGR from the top of
the kidneys to below the bladder at approximately
seven to eight minutes following gadolinium ad-
ministration (TR  190–215 msec, TE  1.3 msec,
flip angle  70°, NEX  1, slice thickness/gap  5
mm/0 mm, matrix size  512  160 [frequency 
phase], frequency selective fat saturation, 20
slices, 24 seconds). Up to four separate acquisi-
tions were acquired to cover the entire urinary
tract. Each of these acquisitions was performed in
a 24-second breathhold. These images are used to
evaluate the wall of the upper tracts and bladder,
identify intraluminal masses that will distort and
displace the contrast enhanced urine, assess the
other abdominal and pelvic organs, and detect en-
larged lymph nodes and bone lesions. These im-
ages provide higher in-plane resolution compared
to the axial reformatted images of the excretory
MRU images, which have limited spatial resolution
due to constraints imposed by scan time limita-
tions; higher resolution increases the scan time
beyond the patient’s ability to suspend respira-
tion.
The total table time was 45 minutes. Gadolinium
(Magnevist; Berlex Wayne, NJ, USA or Omniscan; Am-
ersham Health, Princeton, NJ, USA) was administered
at a dose of 0.1 mmol/kg (maximum 20 mL) through a
20–24-gauge cannula placed in the antecubital fossa at
a rate of 2 mL/second using a power injector (Spectris,
Medrad, Pittsburgh, PA, USA). The arterial/corticomed-
ullary phase acquisition was timed using the auto-
mated contrast-bolus detection technique (Smart Prep;
General Electric Medical Systems).
Image Analysis
The coronal (last phase of sequence #4) and axial (se-
quence #5) excretory phase images of the CE-MRU
studies were independently reviewed by two expert MR
radiologists (H.K.H., R.C.C.) with seven and eight years
of experience in abdominal MR imaging, respectively.
Reviewers evaluated both the source and maximum
intensity projection (MIP) images. The readers were
blinded to the MRU technique (i.e., with or without
furosemide). The readings were done in two sessions
and in each session; each reader was given a random
combination of cases performed with either technique.
The coronal images were interactively reviewed and re-
formatted in multiple planes on a workstation (Advan-
tage Workstation, version 4.0; General Electric Medical
Systems). The multiplanar image reformats were gen-
erated using an MIP algorithm. We did not use subtrac-
tion techniques when evaluating these images.
The upper tracts were divided into five segments:
calyces, renal pelvis, proximal ureter (to the level of the
lower pole of the kidney), middle ureter (between the
lower pole of the kidney and iliac crest), and distal
ureter (from iliac crest to bladder). Readers evaluated
each of the upper tract segments subjectively for the
following: 1) degree of opacification (defined as the pres-
ence of contrast within the segment); 2) distention (as-
sessed qualitatively according to the reader’s ability to
adequately visualize the internal details of the seg-
ment); and 3) the presence of susceptibility and trun-
cation artifacts. These features were evaluated on a
four-point scale as follows: for opacification and disten-
tion (1  poor, 2  fair, 3  adequate, 4  excellent); for
the presence of artifacts (1  none, 2  mild, 3 
moderate, 4  severe artifacts).
Statistical Analysis
Each observer independently scored each segment for
opacification, distention and susceptibility artifact. In-
terobserver disagreement in grading was determined by
a permutation test (17). The difference between each
observer’s scores (indexed by segment with and without
furosemide) was calculated and observer labels were
permuted 10,000 times. There was no significant dif-
ference between observer ratings and their ratings were
therefore averaged. Thus, to determine the effect of fu-
rosemide on upper tract opacification, distention, and
presence of artifacts, a two-sample permutation test
with 10,000 permutations was performed on each seg-
ment. Each test was performed by computing the aver-
age score, for example, of the distention of the calyx
over both observers with and without furosemide. Con-
trol/furosemide labels were permuted and the differ-
ence between average scores with and without furo-
semide was assessed for significance. If the observed
difference in the average was more extreme than 9950
of the 10,000 permutations, then the observed differ-
ence was significant. That is, a P-value of less than
0.005 was considered to be significant. Reducing the
significance level by a factor of 10 (from the standard
0.05) adjusts for the multiple testing that was per-
formed. Permutation tests were used to test hypotheses
in this study as a nonparametric alternative to analysis
of variance methods.
RESULTS
A total of 38 nondilated upper tracts (190 segments) in
22 patients were evaluated including 20 upper tracts
(100 segments) in Group A (saline) and 18 upper tracts
(90 segments) in Group B (saline and furosemide). To
assess for a statistically significant difference in the
interpretation of the two observers, the average differ-
ence of all grades between observers 1 and 2 was cal-
culated and a permutation test with 10,000 permuta-
tions performed. The average difference was –0.06 with
P-value of 0.14, indicating that there is no statistically
significant disagreement in grading between the two
readers.
With regard to opacification, there were no statisti-
cally significant differences in the opacification of any of
the upper tract segments between Group A patients,
who received saline only, and Group B patients, who
received saline and furosemide (Fig. 1a, b; Table 1). No
nonopacified segments were seen in either group. For
reviewer 1, opacification was incomplete (i.e., less than
excellent) in 18 of 20 (90%) patients in Group A and 16
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of 18 (88.9%) patients in Group B, with the proximal
one-third of the ureter being the most common segment
to have less than excellent opacification in both groups.
For reviewer 2, opacification was incomplete in 19 of 20
(95%) patients in Group A with calyces being the most
common segment to have less than excellent opacifica-
tion, and in 14 of 18 (77%) patients in Group B with the
proximal one-third of the ureter being the most com-
mon segment to have less than excellent opacification.
Furosemide, however, significantly improved the de-
gree of calyceal and renal pelvis distention with P-val-
ues less than 0.005 for both segments (Fig. 2a, b). It had
no significant effect on ureteric distention (Table 2).
Furosemide significantly reduced susceptibility and
truncation artifacts throughout the upper tracts with
P-values below 0.001 for all segments (Fig. 3a–c; Table
3). Opacification appeared more homogeneous in
Group B patients compared with Group A. This is likely
due to a combination of improved distention and re-
duced artifacts. Ghosting artifact related to ureteric
peristalsis was not observed.
MRU Findings
The excretory MRU was interpreted as normal in 19
patients and abnormal in three patients. The normal
studies were confirmed at surgery, ureteroscopy, and
follow-up. The three abnormal studies included a pa-
tient with von Hippel Lindau disease who was being
followed after radiofrequency ablation of RCC in both
Figure 1. MRU studies performed in two different patients
using a 3D SPGR sequence (TR/TE/flip angle  6 msec/2.2
msec/35°) without furosemide (a) and with furosemide (b). a: A
38-year-old male with a renal mass on ultrasound, referred for
characterization of the renal mass and assessment of its rela-
tionship to the intrarenal collecting system. Serum creatinine
was 1.1 mg/100 dL and intravenous furosemide was not
given. Note the adequate opacification but poor distention of
the calyces and extensive artifacts (arrows). b: A 48-year-old
male who had undergone a right nephroureterectomy two
years prior for TCC of the renal pelvis. Combined MRI/MRU
was performed to look for potential tumor in the left upper
tract. Serum creatinine was 0.8 mg/dL, and intravenous fu-
rosemide was administered. Note the adequate opacification
and distention of the calyces.
Table 1






Renal pelvis 0.20 0.38
Ureter (proximal 1/3) 0.18 0.47
Ureter (mid 1/3) 0.38 0.22
Ureter (distal 1/3) 0.17 0.53
*No significant effect on upper tract opacification was seen after
Furosemide. Significant P value is 0.005.
Figure 2. MRU studies performed in two different patients
using a 3D SPGR sequence (TR/TE/flip angle  6 msec/2.2
msec/35°) without furosemide (a) and with furosemide (b). a: A
46-year-old female who presented with gross hematuria. MRU
was requested to evaluate urinary symptoms. Serum creati-
nine was 0.6 mg/dL. Combined MRI and MRU was performed
without intravenous furosemide. Note the poor distention of
the intrarenal collecting system (arrow). b: A 62-year-old male
with history of left nephroureterectomy for TCC. Serum creat-
inine was 2.1 mg/dL. Combined MRI and MRU was performed
to rule out recurrent tumor. Intravenous furosemide was ad-
ministered. Note the optimal distention and homogeneous
opacification of the intrarenal collecting system, and the lack
of artifacts (arrow).
Table 2






Renal pelvis 0.69 0.002*
Ureter (proximal 1/3) 0.01 0.17
Ureter (mid 1/3) 0.41 0.46
Ureter (distal 1/3) 0.21 0.92
†Furosemide significantly (*P value 0.005) improved calyceal and
renal pelvis distention but had no significant effect on ureteric dis-
tention.
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kidneys. The excretory MRU done with saline only dem-
onstrated contrast extravasation into the perinephric
space. The second patient had an anastomotic stricture
of the distal right ureter following cystectomy and ileal
loop conduit reconstruction for bladder TCC and had
undergone balloon dilatation of stricture. The MRU
done with furosemide and saline showed minimal re-
sidual narrowing of the ureter at its junction with the
ileal conduit without signs of obstruction. The third
patient was 18 years old and had history surgery at the
age of five years for ureteropelvic junction (UPJ) ob-
struction. The excretory MRU done with furosemide
and saline showed moderate dilatation of the renal pel-
vis with UPJ narrowing but no calyceal dilatation or
other sign of obstruction and was considered a satis-
factory postoperative appearance (Fig. 4a, b). Eight pa-
tients were evaluated for the presence of TCC (primary
hematuria, N  3; follow-up TCC, N  5) and none was
found to have TCC as confirmed by cystoscopy/uret-
eroscopy (N  5), cystoscopy/ureteroscopy and biopsy
(N  1), clinical follow-up for one year (N  1), and
conventional intravenous urography (IVU) (N  1)
DISCUSSION
Excretory contrast-enhanced MRU has been used to
determine the level of obstruction in mild or moderately
dilated systems, to evaluate urinary tract anomalies,
and assess tumor morphology (12–14). 3D excretory
MRU uses similar imaging parameters as MR angiogra-
phy (18) to enhance the appearance of gadolinium-en-
hanced urine and suppress signal from background
soft tissue. Excretory MRU utilizes the same principle of
contrast excretion as conventional IVU and its feasibil-
ity is determined by the ability of the kidneys to excrete
the intravenously administered gadolinium. A techni-
cally adequate excretory MRU study is expected to re-
sult in opacification and adequate distention of the up-
per tracts without artifacts to enable the identification
of filling defects and the evaluation of ureteral wall
abnormalities.
Similar to conventional urography, the production of
a sufficient volume of urine is necessary for the techni-
cal success of excretory MRU. The use of a standard
dose of gadolinium chelate in combination with intra-
venous hydration and low dose furosemide (5–10 mg)
results in a good urographic effect in patients with se-
rum creatinine levels up to 2 mg/100 mL (12). However,
in patients with impaired renal function, an increased
dose of furosemide is required to produce the same
effect (10). The main advantage of CE-MRU is that it can
be performed in patients with impaired renal function,
who cannot tolerate iodinated contrast medium for IVU
or computed tomography (CT) urography studies. Low-
dose gadolinium (up to 0.1 mmol/kg body weight) is not
nephrotoxic in patients with impaired renal function
(19,20), but safety issues with higher doses are contro-
versial (21,22). Only two of our patients, one from
Group A and one from Group B, had creatinine levels
slightly above 2 mg/100 mL. The patient from Group A
(without Lasix [furosemide]) had good opacification, ad-
equate distention, and moderate artifacts compared to
Figure 3. A 47-year-old male who presented with hematuria
underwent MRU using 3D SPGR sequence (TR/TE/flip an-
gle  6 msec/2.2 msec/35°), to rule out a possible TCC. Serum
creatinine level was 1.1 mg/100 dL. Only intravenous saline
was given without furosemide. Note the poor distention of
upper tracts (a) and extensive susceptibility artifact (b; arrow)
seen as dark lines around the calyces and renal pelvis. This
artifact results from the presence of concentrated gadolinium
in the intrarenal collecting system, which causes magnetic
field inhomogeneity and results in spin dephasing. c: Also note
the truncation artifact (arrows) seen as alternating dark and
bright bands paralleling the ureter. This artifact results from
the presence of highly concentrated gadolinium in the ureter.
Table 3






Renal pelvis 1.16 0.001*
Ureter (proximal 1/3) 1.34 0.001*
Ureter (mid 1/3) 1.04 0.001*
Ureter (distal 1/3) 0.89 0.001*
†Furosemide significantly (*P value 0.005) reduced artifacts in all
segments of the upper tracts.
Figure 4. An 18-year-old male who at the age of five years had
surgery for congenital left UPJ obstruction. He was referred for
evaluation of the morphology of the left upper tract after an
ultrasound scan showed moderate pelvicaliectasis. MRU was
performed with intravenous saline and furosemide using a 3D
SPGR sequence (TR/TE/flip angle  6 msec/2.2 msec/35°). a:
Note the moderate dilatation of the left renal pelvis with no
associated calyceal dilatation. b: The cupped, nondilated ca-
lyces are better seen on the magnified view and there is no
renal parenchymal loss. This is considered a satisfactory post-
operative appearance with no evidence to suggest residual
obstruction.
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good opacification, good distention, and no artifacts for
the patient from Group B (with Lasix).
Gadolinium-chelates are hydrophilic low molecular
weight contrast agents that are excreted by the kidneys
through glomerular filtration (23,24). They induce
shortening of T1 and T2 (or T2*) relaxation time. In low
concentrations, i.e., at the clinically used dose of 0.1
mmol/kg, the T1 shortening effect predominates over
the T2 (or T2*) shortening effect, resulting in an in-
crease in the signal intensity of urine on T1-W imaging.
Conversely, at higher concentrations, the T2 (or T2*)
shortening effect predominates, resulting in a decrease
in the signal intensity of urine on T1-W imaging (25).
The T2* effect refers to signal decay that occurs due to
the combination of tissue T2 value and the contribution
from field inhomogeneities. The latter is exaggerated by
the susceptibility effect of concentrated gadolinium.
Since normal kidneys are able to concentrate the ex-
creted gadolinium by a factor of 50–100 (26), T2* effect
of concentrated gadolinium can result in dark signal in
the collecting system on excretory MRU studies. Con-
centrated gadolinium also creates local magnetic field
inhomogeneities, resulting in susceptibility artifacts
and producing zones of signal loss (27). On excretory
MRU images, this artifact can be seen as dark and
bright lines around the collecting system. Highly con-
centrated gadolinium in the upper tract also results in
high contrast interfaces between the gadolinium-filled
ureter and the dark signal from retroperitoneal fat,
which is suppressed by a frequency-selective fat-satu-
ration pulse. This will result in truncation artifacts
when low spatial resolution matrices are used, due to
undersampling of data (27). On excretory MRU images,
truncation artifacts appear as a series of alternating
bands of low and high signal intensity along the phase
encoding axis of the image, parallel to the course of the
ureters. Conspicuity of truncation artifact can be re-
duced either by using a higher resolution imaging ma-
trix or decreasing the contrast at the interface. Since it
is not practically possible to increase the resolution of
the image beyond a certain limit dictated by the pa-
tient’s ability to breathhold, the only alternative solu-
tion is to decrease the contrast interface, which can be
accomplished by diluting the urine within the upper
tracts.
Furosemide is a powerful loop diuretic (28). Its effect
starts immediately after the first pass through the kid-
neys, causing rapid water retention in the tubules (29).
This will increase the fluid in the collecting system,
which helps to dilute the excreted gadolinium and ho-
mogenize its distribution (13), resulting in decreased
T2* effects, susceptibility, and truncation artifacts.
Several techniques have been used to overcome T2*
effect of concentrated gadolinium in excretory CE-MRU
examinations (14,15,30,31) such as the use of oral sa-
line, low dose diuretic, or low dose gadolinium. Szopin-
ski et al (30), in a study of 91 patients, used a very low
dose of Gd-DTPA (0.01 mmol/kg) and had the patients
drink 1 liter of water. A very low dose of gadolinium
without furosemide can be effective in preventing T2*,
but may fail to demonstrate enhancing pathology be-
cause of the inadequate dose of gadolinium. Hughes et
al (31) compared low-dose (total of 2 mL) and high-dose
(0.4 mL/kg) gadolinium-enhanced excretory 3D MRU
for visualization of the calyces, renal pelvis, and ureters
and found that the low gadolinium-dose technique al-
lowed better visualization of calyces and pelvis. This
was attributed to the T2* effect of highly concentrated
gadolinium. No statistically significant difference be-
tween the two techniques was detected with regard to
visualization of the ureters.
Farres et al (14), in a study of 38 patients, compared
visualization of the calyces, pelvis, and ureters in ex-
aminations performed with (N  13) and without (N 
25) 20 mg of intravenous furosemide without intrave-
nous or oral fluid. The authors found improved visual-
ization of calyces and ureters with furosemide. Like-
wise, Nolte-Ernsting et al (10,11,13) reported a positive
effect of furosemide on the quality of excretory CE-
MRU. These authors stated that furosemide initially
induces an increase in urine volume resulting in mild
distention of the urinary tract, then there is the dilu-
tional effect on the excreted gadolinium and the in-
creased urine flow, which leads to rapid and uniform
distribution of gadolinium. Our results are similar to
those reported by Nolte-Ernsting et al (10,11,13), ex-
cept that we did not find a positive effect of furosemide
on the degree of ureteric distention. This may be attrib-
utable to the additional use of intravenous saline in our
patients, which may enhance the “dilution” and “distri-
bution” effect of furosemide. However, our results sug-
gest that intravenous saline alone is not sufficient for
optimal distention of the intrarenal collecting system
and reduction of artifacts, and that furosemide, in ad-
dition to hydration, is essential for adequate distention
of the intrarenal collecting system.
Furosemide is a sulfonamide derivative that may
have cross-reactivity in patients with sensitivity to
other sulfonamides (i.e., sulfonamide antimicrobials,
carbonic anhydrase inhibitors, sulfonylureas, and thi-
azide diuretics) (28,32). No allergic reaction to furo-
semide was reported by any of our patients.
We acknowledge several limitations to our study. We
had no internal control for our patients as we did not
perform a direct comparison of the two techniques in
the same patient. We also did not evaluate the effect of
furosemide alone without saline on the quality of excre-
tory MRU. The variable hydration status and serum
creatinine levels in our patients may have had an im-
pact on the amount of urine produced and gadolinium
excreted by the kidneys, which in turn affected the
resultant image. We attempted to minimize these ef-
fects by giving intravenous saline and increasing the
dose of furosemide in patients with higher creatinine
levels. Additionally, we only evaluated the nondilated
upper tracts, which we consider the most difficult to
adequately distend. It is therefore possible that intra-
venous hydration alone is sufficient to distend the
mildly or moderately dilated upper tract and produce a
technically adequate study. Moreover, we did not at-
tempt to determine the effect of improved upper tract
distention on the detection of urinary tract pathology.
Last, our sample size is relatively small and we did not
do a randomized patient selection.
In conclusion, intravenous furosemide administra-
tion for gadolinium-enhanced excretory MRU studies
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results in rapid and uniform distribution of the ex-
creted gadolinium and helps to minimize T2*, suscep-
tibility, and truncation artifacts throughout the upper
tracts. Furosemide administration improves calyceal
and renal pelvis distention, which improves image qual-
ity. Intravenous saline alone is not sufficient to produce
diagnostic quality MRU studies of the nondilated upper
tracts. We now routinely administer furosemide, in ad-
dition to intravenous saline, to all our patients with
nondilated collecting systems undergoing MRU exami-
nation.
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